Viral infections:

Indications for: EDURANT

In combination with other antiretroviral agents for HIV-1 infection in antiretroviral treatment-naïve patients with HIV-1 RNA ≤100,000 copies/mL at start of therapy. In combination with Vocabria (cabotegravir) for short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine, for use as: oral lead-in to assess the tolerability of rilpivirine prior to administration of Cabenuva (cabotegravir; rilpivirine) extended-release injectable suspensions; or oral therapy for patients who will miss planned injection dosing with Cabenuva.

Adults and Children:

<12yrs or <35kg: not established. Take with a meal. ≥12yrs (≥35kg): 25mg once daily. Pregnancy (already on prior stable dose and with HIV-1 RNA <50 copies/mL): 25mg once daily; monitor viral load. Concomitant rifabutin: 50mg once daily; decrease to 25mg once daily when rifabutin is stopped. In combination with Vocabria: prior to initiation, consult additional full labelings (Vocabria and Cabenuva) to ensure appropriate therapy. Take with a meal at the same time each day. 25mg once daily in combination with Vocabria (30mg/day) for approx. 1 month (≥28 days). As oral lead-in: the last oral dose should be taken on the same day Cabenuva inj is started. As oral replacement (if planned to miss a scheduled Cabenuva inj by >7days): can replace up to 2 consecutive monthly inj visits. The first oral dose should be taken approx. 1 month after the last Cabenuva inj and continued until the day inj dosing is restarted.

EDURANT Contraindications:

Concomitant carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, systemic dexamethasone (more than 1 dose), St. John's wort. Also: use of Cabenuva with rifabutin is contraindicated; see Cabenuva full labeling.

EDURANT Warnings/Precautions:

Prolongation of QTc interval with supratherapeutic doses. Promptly evaluate if depressive symptoms occur. Monitor liver enzymes prior to initiation and during therapy in patients with underlying hepatitis B or C, or marked elevations in transaminases; consider monitoring LFTs in patients without pre-existing hepatic dysfunction or other risks. Discontinue immediately if severe skin or hypersensitivity reactions develop. Severe renal impairment or ESRD: monitor. Pregnancy. Nursing mothers: not recommended.

EDURANT Classification:

Non-nucleoside reverse transcriptase inhibitor.

EDURANT Interactions:

Concomitant NNRTIs (eg, delavirdine): not recommended. Concomitant drugs with a known risk for torsades de pointes: consider alternatives to rilpivirine. Antagonized by CYP3A inducers (see Contraindications). May be potentiated by CYP3A inhibitors (eg, azole antifungals [monitor for breakthrough fungal infections], clarithromycin, erythromycin, telithromycin [consider azithromycin use]). Concomitant methadone; monitor. Separate didanosine, antacids (by at least 2hrs before or at least 4hrs after) and H2-receptor antagonists (by at least 12hrs before or 4hrs after rilpivirine); drugs that increase gastric pH may result in decreased plasma concentrations.

Adverse Reactions:

Depressive disorders, insomnia, headache, rash; hepatotoxicity, fat redistribution, immune reconstitution syndrome.


To register pregnant patients to the Antiretroviral Pregnancy Registry, call (800) 258–4263.

Generic Drug Availability:


How Supplied:


Pricing for EDURANT

25mg tablet (Qty: 30)
Appx. price $1252